Precision TMS: From Generic Pulses to Personalized Brain Care
Precision TMS for depression is an approach to transcranial magnetic stimulation that adjusts stimulation targets, schedules, and parameters to each person’s brain circuits and physiology, instead of applying a single standard protocol to all patients. Transcranial magnetic stimulation is a method of stimulating and resetting brain circuits to relieve symptoms of depression and other brain conditions. It was approved in 2008 for treatment-resistant major depressive disorder and provides substantial benefit to about two-thirds of patients when medications have failed. Yet standard TMS still treats people as interchangeable, despite wide variation in how quickly and how fully they respond. The core claim behind precision TMS is bold: if depression involves disrupted circuits that differ from person to person, then the stimulation ought to be tailored as carefully as a pacemaker setting — and that shift is already underway at UCLA.
The 5x5 Protocol: Compressing Weeks of Treatment into Days
Standard TMS for depression usually means coming to the clinic once a day for six to nine weeks, with relief arriving only after several weeks for many patients. For people already struggling to get out of bed, that schedule is more obstacle than lifeline. UCLA researchers have responded with an aggressive experiment in time: the 5x5 protocol, which delivers five TMS sessions per day for five days, aiming to produce relief within days rather than months. Early evidence suggests that 5x5 appears at least as effective as the longer course while providing much more rapid relief. One quotable takeaway is that “our 5x5 protocol appears to be at least as effective as the longer course of treatment and provides much more rapid relief”. The catch is that this condensed schedule remains off-label and has not yet been reviewed by regulators. Still, the message is clear: when the technology is flexible, the bottleneck becomes imagination, not hardware.
Neuronavigation, Robotics, and Pupils: Personalizing Brain Stimulation in Practice
What makes precision TMS more than a buzzword is the stack of tools UCLA has layered onto routine care. Each patient is seen by an expert psychiatrist at every treatment, and an MRI scan is used to “neuronavigate” to a personalized stimulation target rather than a generic spot on the prefrontal cortex. Robotic systems like the Axilum Cobot position the coil with millimeter accuracy and move with the patient’s head to keep stimulation on target. This is personalized brain stimulation in the literal sense: the machine is driven by that person’s own anatomy. Researchers are also studying pupillometry — how the pupil constricts in response to light — as a window into the autonomic nervous system, which is affected in depression. Baseline pupil constriction amplitude has been linked to symptom improvement, suggesting that pre-treatment pupillary reactivity could help select stimulation frequencies better matched to an individual’s brain response. Precision TMS depression care, in other words, is starting to look like cardiology: guided by imaging, physiology, and continuous feedback rather than guesswork.
Beyond Depression: A Precision Playbook for Complex Mood Disorders
Precision TMS is not happening in isolation; it fits into a broader push to match brain-based treatments to the messy reality of individual mood disorders. UCLA researchers are testing personalized brain stimulation to reset oversensitized circuits in people with long-term symptoms after concussion, using baseline MRI maps to find the specific circuit to disrupt and dampen fear responses and boost coping ability. In parallel, they are part of a large network study that plans to follow 4,000 people with bipolar disorder over five years, collecting brain scans, blood markers, sleep and movement data, and detailed symptom reports. As many as 70% of people with bipolar disorder are misdiagnosed at least once, and clinicians still lack reliable predictors of who will respond to which treatment. The goal is to identify personal characteristics that predict treatment response so patients can spend more time feeling well and choose interventions most likely to help them. Put bluntly, the age of trial-and-error psychiatry has lasted too long; precision TMS is one of the first serious attempts to end it.
The Future of Treatment-Resistant Depression: Faster, Targeted, and Data-Driven
Taken together, UCLA’s work signals a shift in how we treat treatment-resistant depression: away from uniform, slow protocols and toward fast, individualized interventions guided by neurobiology. Transcranial magnetic stimulation already offers substantial benefit to many patients who have not responded to medication, but its impact has been limited by the assumption that one set of parameters suits everyone. Precision TMS rejects that assumption. By using imaging, robotics, physiological markers like pupil response, and even parallel large-scale mood-disorder cohorts, clinicians can start to match the right stimulation pattern to the right brain at the right time. One quotable conclusion is that “our goal is to have more than 85% of patients fully recover from depression with TMS”. That target may be ambitious, but it sets the standard where it belongs: not on incremental gains, but on making rapid, personalized recovery the norm rather than the exception.
